Address
One Bartholomew Close
London, GL EC1A 7BL
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7206 2650
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
October 28, 2003
| Name | Title | Pay | Year Born |
| Timothy Paul McCarthy FCCA | Chairman & Chief Executive Officer | 294,000 | 1956 |
| Sébastien R. Goudreau | Chief Scientific Officer & Director | 3,000 | 1981 |
| Lisa Baderoon | Head of Investor Relations & Non Executive Director | 132,000 | 1966 |
| Timothy Gary Franklin | Chief Operating Officer & Director | 252,000 | 1964 |
| Lara E. Sucheston-Campbell | Head of Clinical & Medical Affairs | 0 | N/A |
| Ashley Louise Clarke | Group Chief Financial Officer & Company Secretary | 0 | N/A |
| Jean-Marie Geiger | Head of Clinical Development | 0 | N/A |
| Laura Mauran-Ambrosino | Head of Research & Development | 0 | N/A |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.